A detailed history of Polar Capital Holdings PLC transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Polar Capital Holdings PLC holds 185,000 shares of DAWN stock, worth $2.41 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
185,000
Previous 935,000 80.21%
Holding current value
$2.41 Million
Previous $12.9 Million 80.0%
% of portfolio
0.02%
Previous 0.08%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.72 - $16.03 $9.54 Million - $12 Million
-750,000 Reduced 80.21%
185,000 $2.58 Million
Q2 2024

Aug 14, 2024

SELL
$12.03 - $17.69 $3.01 Million - $4.42 Million
-250,000 Reduced 21.1%
935,000 $12.9 Million
Q1 2024

May 15, 2024

SELL
$13.56 - $17.46 $2.71 Million - $3.49 Million
-200,000 Reduced 14.44%
1,185,000 $19.6 Million
Q4 2023

Feb 14, 2024

SELL
$9.68 - $15.37 $5.32 Million - $8.45 Million
-550,000 Reduced 28.42%
1,385,000 $20.2 Million
Q3 2023

Nov 14, 2023

BUY
$11.22 - $14.86 $1.8 Million - $2.38 Million
160,385 Added 9.04%
1,935,000 $23.7 Million
Q2 2023

Dec 13, 2023

BUY
$11.74 - $14.47 $4.4 Million - $5.43 Million
375,067 Added 26.8%
1,774,615 $21.2 Million
Q2 2023

Aug 14, 2023

BUY
$11.74 - $14.47 $4.4 Million - $5.43 Million
375,067 Added 26.8%
1,774,615 $21.2 Million
Q1 2023

Dec 13, 2023

SELL
$12.75 - $23.41 $6.83 Million - $12.5 Million
-535,452 Reduced 27.67%
1,399,548 $18.7 Million
Q4 2022

Feb 14, 2023

BUY
$18.77 - $22.0 $3.08 Million - $3.61 Million
163,973 Added 13.27%
1,399,548 $30.1 Million
Q3 2022

Nov 14, 2022

BUY
$16.44 - $26.57 $4.34 Million - $7.01 Million
263,879 Added 27.16%
1,235,575 $24.7 Million
Q2 2022

Aug 15, 2022

BUY
$5.72 - $17.9 $5.56 Million - $17.4 Million
971,696 New
971,696 $17.4 Million

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $956M
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Polar Capital Holdings PLC Portfolio

Follow Polar Capital Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Polar Capital Holdings PLC with notifications on news.